• Home
  • About GPCRCentral

GPCR News

Entries RSS | Comments RSS
  • Tags

    5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
  •  

    June 2008
    M T W T F S S
    « May   Jul »
     1
    2345678
    9101112131415
    16171819202122
    23242526272829
    30  

Elixir present Ghrelin knockout mouse data further validating target

Posted on June 9, 2008 by crimsoncanary

Data presented at the ADA meeting has further validated ghrelin, as a potential target in the treatment of diabetes. Data showed that Ghrelin knockout mice demonstrated a improved metabolic profile when placed on low and high fat diets compared to control mice.

Filed under: gpcr | Tagged: antagonist, Elixir, ghrelin, Research

« Banyu Scientists describe Opioid Receptor Like 1 Antagonists with affinity to the hERG K+ Channel Metabasis present data on glucagon antagonist MB07803 at ADA »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • June 2008
      M T W T F S S
      « May   Jul »
       1
      2345678
      9101112131415
      16171819202122
      23242526272829
      30  
  • Blogroll

    • CrimsonCanary.com
    • GPCRCentral.com
    • IonChannelCentral.com
    • Kinasecentral.com
    • Pharma Company Pipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer